DNTH — Dianthus Therapeutics, Inc. /DE/
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1690585 ·
Last close
$82.07
Market Cap
$4.49B
52W High
$96.50
52W Low
$68.85
ADV30
789,133
Next earnings
2026-05-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 463,000 | — | -46,533,000 | -40,834,000 | 1,246,884,000 | 627,667,000 | 45,570,000 |
| Dec 2025 | 284,000 | — | -69,541,000 | -64,432,000 | 530,922,000 | 51,087,000 | 37,521,000 |
| Sep 2025 | 396,000 | — | -40,288,000 | -36,765,000 | 577,445,000 | 55,984,000 | 30,991,000 |
| Jun 2025 | 193,000 | — | -34,927,000 | -31,629,000 | 326,076,000 | 13,237,000 | 22,997,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-129,060,000
Investing CF
$-122,833,000
Financing CF
$280,125,000
CapEx
$-213,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.10
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-336,729,000
Inventory
—
Receivables
$52,000
ST Investments
$353,208,000
EBIT TTM
$-177,933,000
Pretax Income TTM
$-162,337,000
Interest Exp TTM
—
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,336,000
EBITDA
$-191,172,992
Free Cash Flow
$-71,029,624
Enterprise Value
$3,376,562,688
Total Cash
$1,111,259,008
Total Debt
$1,364,000
Shares Out
54,666,233
Trailing EPS
$-4.23
Book Value
$22.01
ROE
-22.7%
ROA
-15.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,036,000 | -177,933,000 | -162,337,000 | 530,922,000 | 37,521,000 | — | -129,060,000 |
| Dec 2024 | 6,235,000 | -101,864,000 | -84,969,000 | 374,008,000 | 21,531,000 | — | -78,180,000 |
| Dec 2023 | 2,826,000 | -48,174,000 | -43,555,000 | 179,405,000 | 10,535,000 | — | -36,861,000 |
| Dec 2022 | 6,417,000 | -29,705,000 | -28,476,000 | 83,110,000 | 9,454,000 | — | -29,070,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.65
Max Pain — expiry 2026-11-20
max pain strike: $70.00 · spot: $82.51 · call oi: 5,406 · put oi: 11Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GIFLF | Grifols SA | $4.48B | $10.60 | — |
| INDV | Indivior Pharmaceuticals, Inc. | $4.55B | $38.48 | — |
| ERAS | Erasca, Inc. | $4.37B | $14.05 | — |
| ORKA | Oruka Therapeutics, Inc. | $4.22B | $69.89 | — |
| GIKLY | Grifols SA | $4.81B | $5.69 | — |
News headlines (Yahoo Finance, 1h cache)
Dianthus CIDP Data Lift Prospects While Funding And Dilution Risks Linger
2026-06-15 11:09 · Yahoo
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results
2026-06-12 21:13 · Yahoo
Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit
2026-06-10 20:48 · Yahoo
Stocks Settle Sharply Lower on Escalating Middle East Tensions
2026-06-10 20:38 · Yahoo
Stocks Resume Decline as Chipmakers and AI Companies Fall
2026-06-10 15:21 · Yahoo
Stocks Fall on Weakness in Tech and Trucking Companies
2026-06-10 14:09 · Yahoo
Will Orphan Drug Status And Advancing Autoimmune Pipeline Change Dianthus Therapeutics' (DNTH) Narrative
2026-06-10 00:17 · Yahoo
Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline
2026-06-05 15:55 · Yahoo
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier
2026-06-03 17:15 · Yahoo
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-02 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.